Request Demo
Last update 25 Jul 2026
LM-168
Last update 25 Jul 2026
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms LM-168 |
Target |
Action inhibitors |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with LM-168NCT07669415
A Phase II，Open Label,Multicenter Study to Evaluate the Efficacy,Safety,and Tolerability of LM-168 Combined With Other Anti-tumor Therapies in Participants With Advanced Solid Tumor Trials
NCT06868199
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
100 Clinical Results associated with LM-168
Login to view more data
100 Translational Medicine associated with LM-168
Login to view more data
100 Patents (Medical) associated with LM-168
Login to view more data
100 Deals associated with LM-168
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | Australia | 06 May 2025 | |
| Colorectal Cancer | IND Approval | China | 21 Jul 2026 | |
| Esophageal Carcinoma | IND Approval | China | 21 Jul 2026 | |
| Kidney Neoplasms | IND Approval | China | 21 Jul 2026 | |
| Liver Cancer | IND Approval | China | 21 Jul 2026 | |
| Melanoma | IND Approval | China | 21 Jul 2026 | |
| Non-Small Cell Lung Cancer | IND Approval | China | 21 Jul 2026 | |
| Solid tumor | IND Approval | China | 13 Mar 2026 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free